期刊文献+

小分子蛋白酪氨酸激酶抑制剂及其作用机制 被引量:12

Small-molecule inhibitors of protein tyrosine kinases and their mechanisms of action
原文传递
导出
摘要 随着大量的酪氨酸激酶小分子抑制剂的出现以及部分此类药物在临床上抗肿瘤方面的成功应用,对于蛋白酪氨酸激酶抑制剂的研究受到了广泛的关注。本文介绍了已上市的10种蛋白酪氨酸激酶小分子抑制剂,并按作用机制的不同将其分为TypeⅠ和TypeⅡ两类。介绍了两种尚无上市药物的新型的酪氨酸激酶抑制剂,并对开发新酪氨酸激酶抑制剂的方法进行了简介。 As a large number of protein tyrosine kinase inhibitors have been found and some of them were applied to treat cancer patients successfully, the studies of protein tyrosine kinase inhibitors have attracted more and more attention. This paper introduces ten marketed protein tyrosine kinase inhibitors as two groups: Type I and Type Ⅱ , and then introduces two new inhibitors which have not been approved yet. The methods of finding new in- hibitors are also briefly summarized.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第10期1170-1178,共9页 Chinese Journal of New Drugs
基金 国家自然科学基金(21072111 21272131) 山东省自然科学基金(ZR2011BM015)
关键词 抗肿瘤 蛋白酪氨酸激酶 小分子抑制剂 作用机制 antitumor protein tyrosine kinase small-molecule inhibitor mechanism
  • 相关文献

参考文献21

  • 1FOLKMAN J. What is the evidence that tumors are angiogenesis dependent[J]. J Natl Cancer Inst, 1990, 82( 1 ) :4 -6.
  • 2FERRARA N. VEGF and the quest for tumor angiogenesis factors [J]. NatRev Cancer, 2002, 2(10):795-803.
  • 3LIAO JJ. Molecu|ar recognition of protein kinase binding pockets for design of potent and selective klnase inhibitors [ J ].J Med Chem, 2007, 50 ( 3 ) :409 - 424.
  • 4COHEN MS, ZHANG C, SHOKAT KM, et al. Structural bioin- formatics-based design of selective, irreversible kinase inbibitors [J]. Science, 2005, 308(5726):1318-1321.
  • 5彭文,张小猛,张仓,王芳,尤启冬.靶向非活性激酶DFG-out变构结合位点的研究进展[J].中国新药杂志,2012,21(8):890-894. 被引量:3
  • 6HUSE M, KURIYAN J. The eonformational plasticity of protein kinase[J]. Cell, 2002, 109(3): 275 -282.
  • 7SCHNEIDER G, GEPPERT T, HARTENFELLER M, et al. Re- action-driven de novo design, synthesis and testing of potential type ]I kinase inhibitors[J]. Future Med Chem, 2011, 3 (4) : 415 -424.
  • 8FARIVAR RS, GARDNER-THORPE J, ITO H, et al. The effi- cacy of tyrosine kinase inhibitors on human pancreatic cancer cell llnes[J]. JSurgRes, 2003, 115(2) :219 -225.
  • 9安康,柴晓杰,薛飞,王媛,张婷.VEGFR-2与抑制剂Sunitinib的分子对接及分子动力学研究[J].化学学报,2012,70(10):1232-1236. 被引量:4
  • 10TANG PC, SU YD, FENG J, et al. Novel potent orally active mutitargeted receptor tyrosine kinase inhibitors: synthesis, struc- ture-activity relationships, and antitumor activites of 2-indolinone derivatives[ J ]. J Med Chem, 2010, 53 (22) : 8140 - 8149.

二级参考文献108

  • 1GERSHELL L J, ATKINS J H. A brief history of novel drug discovery technologies [ J ]. Nat Rev Drug Discov,2003,2(4) :321 -327.
  • 2HARVEY A L. Natural products in drug discovery [J]. Drug Discov Today, 2008, 13 ( 19/20): 894 - 901.
  • 3HERTZBERG R P, POPE A J. High-throughput screening: new technology for the 21st century [J]. Curr Opin Chem Biol, 2000,4 (4) :445 - 451.
  • 4NEWMAN D J. Natural products as leads to potential drugs:an old process or the new hope for drug discovery? [J]. J Mexi Chem, 2008,51 (9):2589- 2599.
  • 5HOUSTON J G, BANKS M N, BINNIE A, et al. Case study:impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998 - 2006 [ J ]. Drug Discov Today ,2008,13 ( 1/2 ) :44 - 51.
  • 6FATTORI D, SQUARCIA A, BARTOLI S. Fragment-based approach to drug lead discovery:overview and advances in various techniques [ J ]. Drugs R D,2008,9(4) :217 - 227.
  • 7BOEHM H J, BUR D, GMUENDER H, et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods,and 3D guided opfimisation. A promising alternative to random screening [ J ]. J Med Chem, 2000, 43(14) :2664- 2674.
  • 8EDWARDS P D, ALBERT J S, SYLVESTER M, et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency [ J ]. J Med Chem,2007,50 (24) :5912-5925.
  • 9JENCKS W P. On the attribution and additivity of binding energies[ J]. Proc Natl Acad Sci USA, 1981, 78(7) :4046 -4050.
  • 10NAKAMURA C E,ABELES R H. Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme A reductase with strong binding inhibitors:compactin and related compounds[ J]. Biochemistry, 1985,24 ( 6 ) : 1364 - 1376.

共引文献29

同被引文献111

引证文献12

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部